New Leaf Ventures
VC Fund
Vancouver, Canada
New Leaf Ventures is a VC fund in Vancouver focused on Health Care and Medical. New Leaf Ventures provides strategic, structured financing opportunities to undercapitalized ventures.The company is building a scalable business concept transforming cannabis sector opportunities through the application of professional management and targeted investment to achieve sustainable growth and revenues. New Leaf Ventures intends torapidly spur growth at New Leaf USA through the rapid execution of its strategic plan as a demonstration to potential future brand partners the importance and inherent power of the House of Brands (“HOB”) business model. HOB offers tangible benefits for adoption and participation in the NLV multi-state operational concept.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries New Leaf Ventures invests in
Stages New Leaf Ventures invests in
Countries New Leaf Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dax Colwell
|
|||
Michael Stier
|
|||
Terence Lee
|
|||
Investment Focus
Industry
- Health Care 5 (63%)
- Medical 3 (38%)
- Biotechnology 3 (38%)
- Apps 1 (13%)
- SaaS 1 (13%)
Stage
- Series C 3 (38%)
- Series B 2 (25%)
- Pre-Seed 1 (13%)
- Series D 1 (13%)
- Funding Round 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dax Colwell
Co-Founder & Director
|
Co-Founder & Director | Total investments: 0 | Find email | |
|
Michael Stier
President and CEO
|
President and CEO | Total investments: 0 | Find email | |
|
Terence Lee
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Abcuro
|
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $200M / Series C / Feb 12, 2025 | |
|
Abcuro
|
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $155M / Series B / Aug 17, 2023 | |
Windup Minds
|
Windup Minds is a game studio focused on creating VR and MR virtual pet experiences. The company runs a gaming studio that aims to bring virtual pet games to market. | $1.6M / Pre-Seed / Aug 07, 2023 | |
Cleerly
|
Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway.Throughthese data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks. | $223M / Series C / Jul 25, 2022 | |
Edgewise Therapeutics
|
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined itsfoundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. | $95M / Series C / Dec 08, 2020 | |
TigerConnect
|
TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems.Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California. | $45M / Series D / Oct 08, 2020 | |
ESCAPE Bio
|
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiplediseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States. | $73M / Sep 14, 2020 | |
|
ESCAPE Bio
|
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiplediseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States. | $73M / Series B / Sep 14, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does New Leaf Ventures invest in?
New Leaf Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Series C and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact New Leaf Ventures?
Public channels for New Leaf Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at New Leaf Ventures?
The team at New Leaf Ventures includes Dax Colwell (Co-Founder & Director), Michael Stier (President and CEO) and Terence Lee (Chief Financial Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
